The Korean Journal of Pain

  • 제27권1호
  • /
  • Pages.23-29
  • /
  • 2014
  • /
  • 2005-9159(pISSN)
  • /
  • 2093-0569(eISSN)
대한통증학회 (The Korean Pain Society)
권호 표지
DOI QR코드

DOI QR Code

Spinal Noradrenergic Modulation and the Role of the Alpha-2 Receptor in the Antinociceptive Effect of Intrathecal Nefopam in the Formalin Test

  • Jeong, Shin Ho (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School and Hospital) ;
  • Heo, Bong Ha (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School and Hospital) ;
  • Park, Sun Hong (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School and Hospital) ;
  • Kim, Woong Mo (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School and Hospital) ;
  • Lee, Hyung Gon (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School and Hospital) ;
  • Yoon, Myung Ha (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School and Hospital) ;
  • Choi, Jeong Il (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School and Hospital)
  • 투고 : 2013.12.12
  • 심사 : 2013.12.17
  • 발행 : 2014.01.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Nefopam has shown an analgesic effect on acute pain including postoperative pain. The reuptake of monoamines including serotonin and noradrenaline has been proposed as the mechanism of the analgesic action of nefopam, but it remains unclear. Although alpha-adrenergic agents are being widely used in the perioperative period, the role of noradrenergic modulation in the analgesic effect of nefopam has not been fully addressed. Methods: Changes in the antinociceptive effect of intrathecal (i.t.) nefopam against formalin-elicited flinching responses were explored in Sprague-Dawley rats pretreated with i.t. 6-hydroxydopamine (6-OHDA), which depletes spinal noradrenaline. In addition, antagonism to the effect of nefopam by prazosin and yohimbine was evaluated to further elucidate the antinociceptive mechanism of i.t. nefopam. Results: Pretreatment with i.t. 6-OHDA alone did not alter the flinching responses in either phase of the formalin test, while it attenuated the antinociceptive effect of i.t. nefopam significantly during phase 1, but not phase 2. The antagonist of the alpha-2 receptor, but not the alpha-1 receptor, reduced partially, but significantly, the antinociceptive effect of i.t. nefopam during phase 1, but not during phase 2. Conclusions: This study demonstrates that spinal noradrenergic modulation plays an important role in the antinociceptive effect of i.t. nefopam against formalin-elicited acute initial pain, but not facilitated pain, and this action involves the spinal alpha-2 but not the alpha-1 receptor.

키워드

참고문헌

  1. Fuller RW, Snoddy HD. Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice. Neuropharmacology 1993; 32: 995-9. https://doi.org/10.1016/0028-3908(93)90064-A
  2. Rosland JH, Hole K. The effect of nefopam and its enantiomers on the uptake of 5-hydroxytryptamine, noradrenaline and dopamine in crude rat brain synaptosomal preparations. J Pharm Pharmacol 1990; 42: 437-8. https://doi.org/10.1111/j.2042-7158.1990.tb06587.x
  3. Vonvoigtlander PF, Lewis RA, Neff GL, Triezenberg HJ. Involvement of biogenic amines with the mechanisms of novel analgesics. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 651-6. https://doi.org/10.1016/0278-5846(83)90040-4
  4. Esposito E, Romandini S, Merlo-Pich E, Mennini T, Samanin R. Evidence of the involvement of dopamine in the analgesic effect of nefopam. Eur J Pharmacol 1986; 128: 157-64. https://doi.org/10.1016/0014-2999(86)90762-4
  5. Hunskaar S, Fasmer OB, Broch OJ, Hole K. Involvement of central serotonergic pathways in nefopam-induced antinociception. Eur J Pharmacol 1987; 138: 77-82. https://doi.org/10.1016/0014-2999(87)90339-6
  6. Girard P, Coppé MC, Verniers D, Pansart Y, Gillardin JM. Role of catecholamines and serotonin receptor subtypes in nefopam-induced antinociception. Pharmacol Res 2006;54: 195-202. https://doi.org/10.1016/j.phrs.2006.04.008
  7. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66: 355-474. https://doi.org/10.1016/S0301-0082(02)00009-6
  8. Benarroch EE. Descending monoaminergic pain modulation: bidirectional control and clinical relevance. Neurology 2008;71: 217-21. https://doi.org/10.1212/01.wnl.0000318225.51122.63
  9. Cho SY, Park AR, Yoon MH, Lee HG, Kim WM, Choi JI. Antinociceptive effect of intrathecal nefopam and interaction with morphine in formalin-induced pain of rats. Korean J Pain 2013; 26: 14-20. https://doi.org/10.3344/kjp.2013.26.1.14
  10. Bernatzky G, Jurna I. Intrathecal injection of codeine, buprenorphine, tilidine, tramadol and nefopam depresses the tail-flick response in rats. Eur J Pharmacol 1986; 120:75-80. https://doi.org/10.1016/0014-2999(86)90642-4
  11. Fasmer OB, Berge OG, Jørgensen HA, Hole K. Antinociceptive effects of (+/-)-, (+)- and (-)-nefopam in mice. J Pharm Pharmacol 1987; 39: 508-11. https://doi.org/10.1111/j.2042-7158.1987.tb03167.x
  12. Girard P, Pansart Y, Gillardin JM. Nefopam potentiates morphine antinociception in allodynia and hyperalgesia in the rat. Pharmacol Biochem Behav 2004; 77: 695-703. https://doi.org/10.1016/j.pbb.2004.01.018
  13. Tramoni G, Viale JP, Cazals C, Bhageerutty K. Morphinesparing effect of nefopam by continuous intravenous injection after abdominal surgery by laparotomy. Eur J Anaesthesiol 2003; 20: 990-2. https://doi.org/10.1097/00003643-200312000-00013
  14. Kranke P, Eberhart LH, Roewer N, Tramèr MR. Single-dose parenteral pharmacological interventions for the prevention of postoperative shivering: a quantitative systematic review of randomized controlled trials. Anesth Analg 2004; 99:718-27. https://doi.org/10.1213/01.ANE.0000130589.00098.CD
  15. Lu KZ, Shen H, Chen Y, Li MG, Tian GP, Chen J. Ondansetron does not attenuate the analgesic efficacy of nefopam. Int J Med Sci 201; 10: 1790-4.
  16. Höcker J, Gruenewald M, Meybohm P, Schaper C, Scholz J, Steinfath M, et al. Nefopam but not physostigmine affects the thermoregulatory response in mice via alpha(2)-adrenoceptors. Neuropharmacology 2010; 58: 495-500. https://doi.org/10.1016/j.neuropharm.2009.09.001
  17. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci 1992; 12:3665-70.
  18. Suzuki T, Li YH, Mashimo T. The antiallodynic and antihyperalgesic effects of neurotropin in mice with spinal nerve ligation. Anesth Analg 2005; 101: 793-9. https://doi.org/10.1213/01.ANE.0000160582.25368.B9
  19. Uutela P, Reinilä R, Harju K, Piepponen P, Ketola RA, Kostiainen R. Analysis of intact glucuronides and sulfates of serotonin, dopamine, and their phase I metabolites in rat brain microdialysates by liquid chromatography-tandem mass spectrometry. Anal Chem 2009; 81: 8417-25. https://doi.org/10.1021/ac901320z
  20. Shin DJ, Jeong CW, Lee SH, Yoon MH. Receptors involved in the antinociception of intrathecal melatonin in formalin test of rats. Neurosci Lett 2011; 494: 207-10. https://doi.org/10.1016/j.neulet.2011.03.014
  21. Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res 2003; 987: 176-85. https://doi.org/10.1016/S0006-8993(03)03324-9
  22. Shin DJ, Jeong CW, Lee SH, Yoon MH. Receptors involved in the antinociception of intrathecal melatonin in formalin test of rats. Neurosci Lett 2011; 494: 207-10. https://doi.org/10.1016/j.neulet.2011.03.014
  23. Marazziti D, Rotondo A, Ambrogi F, Cassano GB. Analgesia by nefopam: does it act through serotonin? Drugs Exp Clin Res 1991; 17: 259-61.
  24. Ohkubo Y, Nomura K, Yamaguchi I. Involvement of dopamine in the mechanism of action of FR64822, a novel non-opioid antinociceptive compound. Eur J Pharmacol 1991; 204:121-5. https://doi.org/10.1016/0014-2999(91)90695-M
  25. Verleye M, André N, Heulard I, Gillardin JM. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 2004; 1013:249-55. https://doi.org/10.1016/j.brainres.2004.04.035
  26. Novelli A, Díaz-Trelles R, Groppetti A, Fernández-Sánchez MT. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 2005;28: 183-91. https://doi.org/10.1007/s00726-005-0166-0
  27. Verleye M, Gillardin JM. Contribution of transient receptor potential vanilloid subtype 1 to the analgesic and antihyperalgesic activity of nefopam in rodents. Pharmacology 2009; 83: 116-21. https://doi.org/10.1159/000186050
  28. Nakajima K, Obata H, Iriuchijima N, Saito S. An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. Pain 2012; 153: 990-7. https://doi.org/10.1016/j.pain.2012.01.029
  29. Romero TR, Resende LC, Guzzo LS, Duarte ID. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg 2013; 116: 463-72. https://doi.org/10.1213/ANE.0b013e3182707859
  30. Wada T, Hasegawa Y, Ono H. Characterization of alpha1- adrenoceptor subtypes in facilitation of rat spinal motoneuron activity. Eur J Pharmacol 1997; 340: 45-52. https://doi.org/10.1016/S0014-2999(97)01406-4
  31. Yaksh TL. Central pharmacology of nociceptive transmission. In: Wall and Melzack's textbook of pain. 5th ed. Edited by McMahon SB, Koltzenburg M. Philadelphia (PA), Elsevier.2006, pp 371-414.
  32. Day HE, Campeau S, Watson SJ Jr, Akil H. Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat 1997; 13: 115-39. https://doi.org/10.1016/S0891-0618(97)00042-2
  33. Gil DW, Cheevers CV, Kedzie KM, Manlapaz CA, Rao S, Tang E, et al. Alpha-1-adrenergic receptor agonist activity of clinical alpha-adrenergic receptor agonists interferes with alpha-2-mediated analgesia. Anesthesiology 2009; 110:401-7.
  34. Van Elstraete AC, Sitbon P. Median effective dose (ED50) of paracetamol and nefopam for postoperative pain: isobolographic analysis of their antinociceptive interaction. Minerva Anestesiol 2013; 79: 232-9.
  35. Girard P, Verniers D, Coppé MC, Pansart Y, Gillardin JM. Nefopam and ketoprofen synergy in rodent models of antinociception. Eur J Pharmacol 2008; 584: 263-71. https://doi.org/10.1016/j.ejphar.2008.02.012
  36. Delage N, Maaliki H, Beloeil H, Benhamou D, Mazoit JX. Median effective dose (ED50) of nefopam and ketoprofen in postoperative patients: a study of interaction using sequential analysis and isobolographic analysis. Anesthesiology 2005;102: 1211-6. https://doi.org/10.1097/00000542-200506000-00022

피인용 문헌

  1. Expression of the spinal 5-HT7 receptor and p-ERK pathway in the carrageenan inflammatory pain of rats vol.68, pp.2, 2015, https://doi.org/10.4097/kjae.2015.68.2.170
  2. What do monoamines do in pain modulation? vol.10, pp.2, 2016, https://doi.org/10.1097/SPC.0000000000000207
  3. Anti-allodynic effect of intrathecal processed Aconitum jaluense is associated with the inhibition of microglial activation and P2X7 receptor expression in spinal cord vol.16, pp.1, 2016, https://doi.org/10.1186/s12906-016-1201-2
  4. The Role of Spinal Dopaminergic Transmission in the Analgesic Effect of Nefopam on Rat Inflammatory Pain vol.29, pp.3, 2016, https://doi.org/10.3344/kjp.2016.29.3.164
  5. Opioid sparing effect and safety of nefopam in patient controlled analgesia after laparotomy: A randomized, double blind study vol.44, pp.4, 2016, https://doi.org/10.1177/0300060516650783
  6. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain vol.876, pp.None, 2014, https://doi.org/10.1016/j.ejphar.2020.173062